Scroll

mifepristone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
steroidal compounds acting on progesterone receptors	1805	84371-65-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mifepristone mifegyne mifeprex mifestone	A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME. Molecular weight: 429.60 Formula: C29H35NO2 CLOGP: 4.47 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 40.54 ALOGS: -5.11 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mifepristone
mifegyne
mifeprex
mifestone

A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.

Molecular weight: 429.60
Formula: C29H35NO2
CLOGP: 4.47
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 40.54
ALOGS: -5.11
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O
0.20	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	69 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
MRTD (Maximum Recommended Therapeutic Daily Dose)	23.28 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
t_half (Half-life)	16.60 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.45 L/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Sept. 28, 2000	FDA	DANCO LABS LLC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abortion incomplete	4663.45	50.32	666	4193	2465	63481698
Haemorrhage	2421.19	50.32	613	4246	60409	63423754
Pregnancy	763.98	50.32	224	4635	36612	63447551
Endometritis	447.78	50.32	76	4783	942	63483221
Anaemia	267.56	50.32	202	4657	293228	63190935
Drug ineffective for unapproved indication	186.87	50.32	77	4782	33986	63450177
Induced abortion failed	183.26	50.32	29	4830	223	63483940
Muscle spasms	149.36	50.32	111	4748	156039	63328124
Retained products of conception	124.30	50.32	19	4840	113	63484050
Abortion induced incomplete	123.15	50.32	16	4843	19	63484144

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Abortion incomplete	4832.30	47.65	662	3958	2402	79737366
Haemorrhage	2319.43	47.65	607	4013	90511	79649257
Pregnancy	896.23	47.65	224	4396	26627	79713141
Endometritis	442.29	47.65	70	4550	738	79739030
Anaemia	238.86	47.65	200	4420	444815	79294953
Induced abortion failed	189.39	47.65	28	4592	178	79739590
Muscle spasms	161.23	47.65	109	4511	174621	79565147
Retained products of conception	138.36	47.65	20	4600	106	79739662
Drug ineffective for unapproved indication	108.82	47.65	55	4565	51183	79688585
Abortion induced incomplete	103.42	47.65	13	4607	16	79739752

Showing 1 to 10 of 22 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	G03XB01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Progesterone receptor modulators
ATC	G03XB51	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Progesterone receptor modulators
CHEBI has role	CHEBI:49020	hormone antagonists
CHEBI has role	CHEBI:49323	contraceptive drugs
CHEBI has role	CHEBI:49326	synthetic oral contraceptives
CHEBI has role	CHEBI:50691	abortifacient drug
FDA EPC	N0000175841	Progestin Antagonist
FDA MoA	N0000000115	Progestational Hormone Receptor Antagonists
MeSH PA	D000019	Abortifacient Agents
MeSH PA	D000021	Abortifacient Agents, Steroidal

Showing 1 to 10 of 19 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Pregnancy with abortive outcome	indication	363681007
Severe adrenal insufficiency	contraindication	24867002
Ectopic pregnancy	contraindication	34801009	DOID:0060329
Erythropoietic protoporphyria	contraindication	51022005	DOID:13270
Hepatic porphyria	contraindication	55056006	DOID:3133
Variegate porphyria	contraindication	58275005	DOID:4346
Porphyria cutanea tarda	contraindication	61860000	DOID:3132
Blood coagulation disorder	contraindication	64779008	DOID:1247
Intermenstrual bleeding - irregular	contraindication	64996003
Miscarriage with sepsis	contraindication	67465009

Showing 1 to 10 of 17 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.08	acidic
pKa2	3.7	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	8921348	Aug. 27, 2028	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	10842801	Nov. 15, 2032	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	10500216	March 5, 2033	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	10166242	April 20, 2036	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	10166243	April 20, 2036	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	10660904	April 20, 2036	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	9943526	April 20, 2036	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	10006924	Aug. 12, 2036	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	10495650	Aug. 12, 2036	TREATING CUSHINGS SYNDROME
300MG	KORLYM	CORCEPT THERAP	N202107	Feb. 17, 2012	RX	TABLET	ORAL	9829495	Aug. 15, 2036	TREATING CUSHINGS SYNDROME

Showing 1 to 10 of 16 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	ANTAGONIST	IC50	9	WOMBAT-PK	CHEMBL
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN	ANTAGONIST	Ki	8.74	WOMBAT-PK	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Ki	6.64	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	4.92	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN	AGONIST	EC50	5	IUPHAR
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.10	DRUG MATRIX
Mineralocorticoid receptor	Nuclear hormone receptor	P08235	MCR_HUMAN		IC50	5.68	WOMBAT-PK
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN		IC50	5.30	CHEMBL
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		Ki	8.33	WOMBAT-PK
Estrogen receptor beta	Nuclear hormone receptor	Q92731	ESR2_HUMAN		Ki	5.54	CHEMBL

Showing 1 to 10 of 23 entries

Previous1 2 3Next

External reference:

Show entries

Search:

ID	Source
486	PDB_CHEM_ID
004008	NDDF
129483007	SNOMEDCT_US
15775	MMSL
231857	MMSL
2805	IUPHAR_LIGAND_ID
284781	RXNORM
320T6RNW1F	UNII
395796009	SNOMEDCT_US
4021235	VUID

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Korlym	HUMAN PRESCRIPTION DRUG LABEL	1	76346-073	TABLET	300 mg	ORAL	NDA	28 sections
Korlym	HUMAN PRESCRIPTION DRUG LABEL	1	76346-073	TABLET	300 mg	ORAL	NDA	28 sections
Korlym	HUMAN PRESCRIPTION DRUG LABEL	1	76346-073	TABLET	300 mg	ORAL	NDA	28 sections
Mifepristone	HUMAN PRESCRIPTION DRUG LABEL	1	43393-001	TABLET	200 mg	ORAL	ANDA	21 sections
Mifepristone	HUMAN PRESCRIPTION DRUG LABEL	1	43393-001	TABLET	200 mg	ORAL	ANDA	21 sections

Showing 1 to 5 of 5 entries

Previous1Next